orthumbria osteoporosis project: Group clinics

Completed

• Conditions: Specialty: Musculoskeletal disorders, Primary sub-specialty: Metabolic Bone Disease; Musculoskeletal Diseases; Metabolic Bone Disease

• Registration Number: ISRCTN56916730
• Lead Sponsor: orth Tyneside General Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-09-01
• Last Update Posted: 20 November 2017

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 214

Inclusion Criteria

1. Patients identified as high risk of an osteoporotic fracture, needing treatment
2. Patients aged 50 years and over
3. Patients giving informed consent to the study

Exclusion Criteria

1. Patients not eligible for first line treatment as defined by North of Tyne Osteoporosis Guidance (encompassing FRAX calculation and NOGG guideline)
2. Patients not wishing to participate in the study
3. Patients unable to consent to participate in the study
4. Patient contraindications to bisphosphonates (upper gastrointestinal problems, severe impairment GFR<35ml/min, previous intolerance)
5. Terminally ill patients
6. Housebound patients

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mean possession ratio (MPR) of bisphosphonates is measured using practice prescription records at 12 months

Secondary Outcome Measures

Name	Time	Method
1. Persistence with treatment is the time (in months) before the drug is no longer requested measured using practice prescription records by month up to 12 months<br>2. Patient satisfaction with group clinics, enabling factors and active ingredients were explored with qualitative interviews of osteoporosis group clinic participants and comparison with an established, but co-designed and therefore evolving inflammatory arthritis group clinic model<br>3. Cost analysis of the intervention was restricted to staff costs of, as assumptions of other costs being equivalent were met